The biological activity of G-quadruplex DNA binding papaverine-derived ligand in breast cancer cells.
It was shown previously that the papaverine oxidation products 6a,12a-diazadibenzo-[a,g]fluorenylium derivative (ligand 1) and 2,3,9,10-tetramethoxy-12-oxo-12H-indolo[2,1-a]isoquinolinium chloride (ligand 2) bind to guanine-quadruplexes (G4) of single stranded G-rich 3'-overhangs of mammalian telomeric DNA. Here we show the biological activity of ligand 1. This compound exhibit antiproliferative activity in MCF-7 cells (IC(50) for ligand 1 = 14.16 +/- 0.01 microM, 24 h, 1.158 +/- 0.056 microM, 72 h. PCNA levels were not altered after treatment of MCF-7 cells with concentrations of ligand 1 which, however, led to alterations in the cell cycle. 5 and 10 microM of the ligand 1 arrested cells in the G0/G1 phase of the cell cycle and this led to a decrease of cells in the S phase. Intracellular accumulation of ligand 1 was observed even after a cell passage and medium exchange in fluorescence microscopy while low concentrations of ligand 1 (0.001 to 0.1 microM) inhibited telomerase activity as shown by TRAP assay.
Rubis
Blazej
B
Department of Clinical Chemistry and Molecular Diagnostics, Poznan University of Medical Sciences, Poznan, Poland.
Kaczmarek
Mariusz
M
Szymanowska
Natalia
N
Galezowska
Elzbieta
E
Czyrski
Andrzej
A
Juskowiak
Bernard
B
Hermann
Tadeusz
T
Rybczynska
Maria
M
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004247:DNA / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D054856:G-Quadruplexes; D006801:Humans; D020128:Inhibitory Concentration 50; D008024:Ligands; D008856:Microscopy, Fluorescence; D010084:Oxidation-Reduction; D010208:Papaverine / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D018809:Proliferating Cell Nuclear Antigen / Q000187:drug effects / Q000378:metabolism; D019098:Telomerase / Q000037:antagonists & inhibitors
D008024:Ligands; D018809:Proliferating Cell Nuclear Antigen; D004247:DNA; D010208:Papaverine; D019098:Telomerase
J Biol Chem. 2007 Jun 1;282(22):16441-53
17428792
Clin Transl Oncol. 2007 Mar;9(3):145-54
17403625
Nucleic Acids Res. 2002 Feb 15;30(4):839-65
11842096
Eur J Cancer. 2005 Dec;41(18):2873-81
16253503
J Neurooncol. 2000 Mar;47(1):39-46
10930098
Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2672-7
11854467
J Clin Periodontol. 2004 Sep;31(9):758-63
15312098
Oncogene. 2005 Apr 21;24(18):2917-28
15735722
Mol Pharmacol. 2002 May;61(5):1154-62
11961134
Cancer Res. 1987 Feb 15;47(4):936-42
3802100
Nat Rev Drug Discov. 2006 Jul;5(7):577-84
16773071
J Biomol Struct Dyn. 1992 Feb;9(4):643-52
1616623
Cell. 2001 Sep 21;106(6):661-73
11572773
Science. 1994 Dec 23;266(5193):2011-5
7605428
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2635-9
8610093
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1871-6
15681588
Eur J Pharmacol. 2003 Aug 8;474(2-3):141-7
12921855
Cancer Res. 2005 Feb 15;65(4):1489-96
15735037
Curr Opin Genet Dev. 2003 Feb;13(1):70-6
12573438
Nature. 1991 Apr 25;350(6320):718-20
2023635
Mol Pharmacol. 2004 Nov;66(5):1138-46
15304549
Curr Opin Pharmacol. 2002 Aug;2(4):415-23
12127874
Int J Oncol. 2004 Jun;24(6):1481-7
15138591
Oncogene. 2002 Jan 21;21(4):553-63
11850780
Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17347-52
17954919
Curr Opin Struct Biol. 2003 Jun;13(3):275-83
12831878
Mol Cancer Ther. 2002 Jun;1(8):565-73
12479216
J Med Chem. 1997 Jul 4;40(14):2113-6
9216827
Curr Pharm Des. 2000 Mar;6(4):441-78
10788591
Mol Cancer Ther. 2004 Oct;3(10):1201-6
15486186
Microbiol Mol Biol Rev. 2002 Sep;66(3):407-25, table of contents
12208997
J Med Chem. 2003 Oct 9;46(21):4463-76
14521409
Int J Biol Macromol. 2007 Dec 1;41(5):558-63
17719085
Nucleic Acids Res. 2007;35(22):7429-55
17913750
Mol Pharmacol. 2001 Nov;60(5):981-8
11641426
Circulation. 1998 Jul 7;98(1):82-9
9665064
Nat Rev Drug Discov. 2002 May;1(5):383-93
12120414